Scarica l'app Stockscreener
30.99
3.14%
-1.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook - Finviz
VKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring A 178% Upside Potential - DirectorsTalk Interviews
Viking Therapeutics (VKTX) Stock: Financial Performance Highlights 22% Revenue Growth and 44% Profit Increase in 2025 - MEXC
Viking Therapeutics, Inc. (VKTX) Stock: Revenue Surges 22% as Adjusted Net Income Jumps 44% in 2025 - MEXC
Rafferty Asset Management LLC Purchases 41,888 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Getting Closer To Key Technical Benchmark - Investor's Business Daily
Vanguard Group Reduces Stake in Viking Therapeutics - National Today
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
Viking Therapeutics, Inc. $VKTX Shares Sold by Vanguard Group Inc. - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Upgraded at BTIG Research - MarketBeat
Viking Therapeutics (VKTX) Is Up 9.1% After Advancing VK2735 As Rival Obesity Drug Stumbles - simplywall.st
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today - Yahoo Finance
Viking Therapeutics: The High-Stakes Weight Loss Contender - MarketBeat
Viking Therapeutics Advances VK2735 As Obesity Data And Valuation Draw Focus - simplywall.st
Viking Therapeutics Gains Ground Amid Novo Nordisk's Clinical Setback - AD HOC NEWS
Is Viking Therapeutics (VKTX) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - The Motley Fool
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - 富途牛牛
Viking Therapeutics Advances VK2735 As Phase 3 Trials Shape Valuation - simplywall.st
Viking Therapeutics Gains Momentum as Rival Stumbles - AD HOC NEWS
Viking Therapeutics Shares Surge as Rival Stumbles in Obesity Drug Race - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Investor Outlook: A 169% Upside Potential Sparks Interest - DirectorsTalk Interviews
Viking Therapeutics, Inc. (VKTX): A bull case theory - MSN
Viking Therapeutics Stock Jumps 11% After Obesity Drug Update: Analysts See $93 Target - TIKR.com
Viking Therapeutics Gains Momentum in Competitive Weight-Loss Drug Arena - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Bitget
The Ultimate Biotech Stock to Buy With $500 Right Now - AOL.com
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. - The Globe and Mail
Viking Therapeutics Targets Expansion Amid Market Challenges - timothysykes.com
Viking Therapeutics Stock Gains Amid Obesity Drug Buzz - Benzinga
Viking Therapeutics (VKTX) Valuation In Focus As VK2735 Advances In GLP 1 Weight Loss Trials - simplywall.st
Why Viking Therapeutics Stock Is Climbing Again - TipRanks
Why Viking Therapeutics Stock Is Up More Than 9% Today - Yahoo Finance
Viking Therapeutics (VKTX) Sees Significant 10.7% Share Price In - GuruFocus
Viking Therapeutics Stock (VKTX) Opinions on Novo Nordisk CagriSema Setback - Quiver Quantitative
Viking Therapeutics Shares Surge as Rival's Obesity Drug Stumbles - AD HOC NEWS
Viking Therapeutics: VK2735 Promise Meets Execution Risk - AlphaStreet News
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds - Nasdaq
Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate - AOL.com
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN
Viking Therapeutics Surges as Obesity Drug Hopes Rise - TipRanks
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. - AOL.com
Viking Therapeutics (NASDAQ:VKTX) Stock Rating Upgraded by Zacks Research - MarketBeat
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity - MSN
Can Viking Therapeutics Really Soar 300%? Why Wall Street Is Betting Big on This Biotech Stock - NAI500
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street - AOL.com
Is Viking Therapeutics Stock Really Going to $125? - AOL.com
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
$100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Viking Therapeutics plans to advance oral obesity drug to late-stage testing - MSN
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast - Investing.com Nigeria
3.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):